Global Interleukin Inhibitors Market 2026-2035
Description
Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Type (IL-17, IL-23, IL-1, IL-5, IL-6 and Others) and by Application (Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Cancer and Others), (2026-2035)
Industry Overview
Interleukin inhibitors market was valued at $28.8 billion in 2025 and is projected to reach $79.0 billion by 2035, growing at a CAGR of 10.6% during the forecast period (2026-2035). The global interleukin inhibitors market is experiencing steady growth driven by the rising prevalence of chronic inflammatory and autoimmune disorders such as rheumatoid arthritis, asthma, and inflammatory bowel disease. Increasing adoption of targeted biologic therapies, including IL-17, IL-23, IL-1, IL-5, and IL-6 inhibitors, is further accelerating market expansion. Advancements in biotechnology and ongoing clinical research have contributed to the development of more effective and safer therapeutic options. Favorable regulatory approvals and an expanding pipeline of innovative biologics are supporting sustained industry growth. Additionally, growing healthcare expenditure and improved access to specialty treatments across emerging economies are strengthening market penetration. Strategic collaborations among pharmaceutical companies and continued investment in research and development are expected to reinforce long-term market advancement through 2035.
Market Dynamics
Expansion of Advanced Diagnostic Testing Capabilities
The Interleukin inhibitors market is witnessing a notable shift toward advanced diagnostic testing, including molecular diagnostics, genetic testing, and tumor profiling. Laboratories are increasingly integrating high-throughput and automated platforms to improve accuracy, efficiency, and turnaround times. The growing clinical relevance of personalized medicine has elevated demand for specialized testing services across oncology and immunology. Healthcare providers are prioritizing comprehensive diagnostic insights to support precise treatment decisions. This trend is strengthening the role of laboratories as critical partners in patient care delivery. Continued investment in advanced testing infrastructure is expected to further enhance service capabilities over the forecast period.
Expansion of Molecular and Genetic Diagnostic Services
The Interleukin inhibitors market is observing increased adoption of molecular and genetic diagnostic testing across multiple disease areas. Laboratories are expanding capabilities in oncology, inherited disorders, and infectious disease detection to support precision-based clinical decision-making. Demand for advanced testing has encouraged service providers to invest in specialized platforms and skilled personnel. Large reference laboratories are strengthening their genetic testing portfolios to address growing clinical complexity. This shift is also supported by improved clinician awareness and broader test reimbursement. As testing sophistication rises, molecular diagnostics continue to reshape service offerings across the market.
Market Segmentation
Among product categories, IL-17 inhibitors represent one of the largest revenue-generating segments owing to their established efficacy in treating chronic inflammatory disorders. Strong clinical outcomes in psoriasis, psoriatic arthritis, and ankylosing spondylitis have reinforced physician preference for this class of biologics. Companies such as Novartis and Eli Lilly and Company continue to strengthen their portfolios through lifecycle management strategies and expanded indications. Increased biologic adoption supported by favorable reimbursement policies in developed economies has further accelerated uptake. Recent trends indicate sustained investment in next-generation monoclonal antibodies designed to improve dosing convenience and long-term safety. Ongoing comparative clinical studies are enhancing competitive positioning within this category. Continuous regulatory approvals across new geographic markets are expected to preserve its leading market share.
Asthma Applications Exhibit Rapid Growth Momentum
Within therapeutic applications, asthma is emerging as one of the fastest expanding segments due to rising global prevalence and improved diagnostic rates. Growing awareness of severe eosinophilic asthma has increased demand for targeted IL-5 and IL-6 inhibitors that address underlying inflammatory pathways. Market participants including GlaxoSmithKline and AstraZeneca are actively advancing biologic therapies to strengthen their respiratory portfolios. Expanding clinical evidence supporting biologics as add-on therapies has driven broader physician acceptance. Recent developments highlight the introduction of long-acting formulations aimed at enhancing patient adherence. Healthcare systems are progressively incorporating advanced biologics into treatment guidelines, supporting sustained adoption. Increased research into precision medicine approaches is anticipated to further accelerate segment expansion over the forecast horizon.
Regional Outlook
The global interleukin inhibitors market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Strengthens Its Leadership through Innovation and Strategic Expansion
North America continues to demonstrate strong momentum in the interleukin inhibitors sector, supported by advanced biologics research and early adoption of targeted immunotherapies. The rising incidence of autoimmune and inflammatory disorders has sustained demand for IL-17 and IL-23 inhibitors across the United States and Canada. Leading pharmaceutical manufacturers such as Pfizer, Johnson & Johnson, and AbbVie maintain a significant regional presence through continuous product innovation and strategic partnerships. Recent approvals of next-generation monoclonal antibodies and expanded indications for existing biologics have strengthened treatment accessibility. Favorable reimbursement frameworks and growing investment in specialty care infrastructure further contribute to sustained market expansion. Ongoing clinical trials targeting novel inflammatory pathways are expected to reinforce regional leadership over the forecast period.
Asia Pacific Emerges as a High-Growth Hub Driven by Healthcare Advancements
Asia Pacific is emerging as a high-growth region, driven by expanding healthcare infrastructure and a rising patient pool affected by chronic immune-mediated conditions. Increasing awareness regarding biologic therapies has encouraged the uptake of IL-6 and IL-5 inhibitors in key markets such as China, Japan, and India. Regional expansion strategies by global companies including Novartis and Roche, alongside domestic manufacturers, have intensified competitive activity. Governments across the region are promoting research collaborations and accelerating regulatory pathways for innovative biologics. Recent trends indicate growing investment in biosimilar development to improve affordability and broaden treatment access. Strengthening distribution networks and localized manufacturing capabilities are anticipated to sustain long-term regional growth.
Market Players Outlook
The major companies operating in the global interleukin inhibitors market include AbbVie Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Sanofi S.A. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
Industry Overview
Interleukin inhibitors market was valued at $28.8 billion in 2025 and is projected to reach $79.0 billion by 2035, growing at a CAGR of 10.6% during the forecast period (2026-2035). The global interleukin inhibitors market is experiencing steady growth driven by the rising prevalence of chronic inflammatory and autoimmune disorders such as rheumatoid arthritis, asthma, and inflammatory bowel disease. Increasing adoption of targeted biologic therapies, including IL-17, IL-23, IL-1, IL-5, and IL-6 inhibitors, is further accelerating market expansion. Advancements in biotechnology and ongoing clinical research have contributed to the development of more effective and safer therapeutic options. Favorable regulatory approvals and an expanding pipeline of innovative biologics are supporting sustained industry growth. Additionally, growing healthcare expenditure and improved access to specialty treatments across emerging economies are strengthening market penetration. Strategic collaborations among pharmaceutical companies and continued investment in research and development are expected to reinforce long-term market advancement through 2035.
Market Dynamics
Expansion of Advanced Diagnostic Testing Capabilities
The Interleukin inhibitors market is witnessing a notable shift toward advanced diagnostic testing, including molecular diagnostics, genetic testing, and tumor profiling. Laboratories are increasingly integrating high-throughput and automated platforms to improve accuracy, efficiency, and turnaround times. The growing clinical relevance of personalized medicine has elevated demand for specialized testing services across oncology and immunology. Healthcare providers are prioritizing comprehensive diagnostic insights to support precise treatment decisions. This trend is strengthening the role of laboratories as critical partners in patient care delivery. Continued investment in advanced testing infrastructure is expected to further enhance service capabilities over the forecast period.
Expansion of Molecular and Genetic Diagnostic Services
The Interleukin inhibitors market is observing increased adoption of molecular and genetic diagnostic testing across multiple disease areas. Laboratories are expanding capabilities in oncology, inherited disorders, and infectious disease detection to support precision-based clinical decision-making. Demand for advanced testing has encouraged service providers to invest in specialized platforms and skilled personnel. Large reference laboratories are strengthening their genetic testing portfolios to address growing clinical complexity. This shift is also supported by improved clinician awareness and broader test reimbursement. As testing sophistication rises, molecular diagnostics continue to reshape service offerings across the market.
Market Segmentation
- Based on the type, the market is segmented into IL-17, IL-23, IL-1, IL-5, IL-6 and others.
- Based on the range, the market is segmented into hospital-based laboratories, stand-alone laboratories, clinic-based laboratories and others.
Among product categories, IL-17 inhibitors represent one of the largest revenue-generating segments owing to their established efficacy in treating chronic inflammatory disorders. Strong clinical outcomes in psoriasis, psoriatic arthritis, and ankylosing spondylitis have reinforced physician preference for this class of biologics. Companies such as Novartis and Eli Lilly and Company continue to strengthen their portfolios through lifecycle management strategies and expanded indications. Increased biologic adoption supported by favorable reimbursement policies in developed economies has further accelerated uptake. Recent trends indicate sustained investment in next-generation monoclonal antibodies designed to improve dosing convenience and long-term safety. Ongoing comparative clinical studies are enhancing competitive positioning within this category. Continuous regulatory approvals across new geographic markets are expected to preserve its leading market share.
Asthma Applications Exhibit Rapid Growth Momentum
Within therapeutic applications, asthma is emerging as one of the fastest expanding segments due to rising global prevalence and improved diagnostic rates. Growing awareness of severe eosinophilic asthma has increased demand for targeted IL-5 and IL-6 inhibitors that address underlying inflammatory pathways. Market participants including GlaxoSmithKline and AstraZeneca are actively advancing biologic therapies to strengthen their respiratory portfolios. Expanding clinical evidence supporting biologics as add-on therapies has driven broader physician acceptance. Recent developments highlight the introduction of long-acting formulations aimed at enhancing patient adherence. Healthcare systems are progressively incorporating advanced biologics into treatment guidelines, supporting sustained adoption. Increased research into precision medicine approaches is anticipated to further accelerate segment expansion over the forecast horizon.
Regional Outlook
The global interleukin inhibitors market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Strengthens Its Leadership through Innovation and Strategic Expansion
North America continues to demonstrate strong momentum in the interleukin inhibitors sector, supported by advanced biologics research and early adoption of targeted immunotherapies. The rising incidence of autoimmune and inflammatory disorders has sustained demand for IL-17 and IL-23 inhibitors across the United States and Canada. Leading pharmaceutical manufacturers such as Pfizer, Johnson & Johnson, and AbbVie maintain a significant regional presence through continuous product innovation and strategic partnerships. Recent approvals of next-generation monoclonal antibodies and expanded indications for existing biologics have strengthened treatment accessibility. Favorable reimbursement frameworks and growing investment in specialty care infrastructure further contribute to sustained market expansion. Ongoing clinical trials targeting novel inflammatory pathways are expected to reinforce regional leadership over the forecast period.
Asia Pacific Emerges as a High-Growth Hub Driven by Healthcare Advancements
Asia Pacific is emerging as a high-growth region, driven by expanding healthcare infrastructure and a rising patient pool affected by chronic immune-mediated conditions. Increasing awareness regarding biologic therapies has encouraged the uptake of IL-6 and IL-5 inhibitors in key markets such as China, Japan, and India. Regional expansion strategies by global companies including Novartis and Roche, alongside domestic manufacturers, have intensified competitive activity. Governments across the region are promoting research collaborations and accelerating regulatory pathways for innovative biologics. Recent trends indicate growing investment in biosimilar development to improve affordability and broaden treatment access. Strengthening distribution networks and localized manufacturing capabilities are anticipated to sustain long-term regional growth.
Market Players Outlook
The major companies operating in the global interleukin inhibitors market include AbbVie Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Sanofi S.A. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In March 2025, Johnson & Johnson announced that the US Food and Drug Administration (FDA) approved TREMFYA (guselkumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract. TREMFYA is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.
- In April 2024, ImmunityBio, Inc. announced that the FDA approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global interleukin inhibitors market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
230 Pages
- 1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Interleukin inhibitors Market Sales Analysis – Type Application ($ Million)
- Interleukin inhibitors Market Sales Performance of Top Countries
- 1.1. Research Methodology
- Primary Research Approach
- Secondary Research Approach
- 1.2. Market Snapshot
- 2. Market Overview and Insights
- 2.1. Scope of the Study
- 2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Interleukin inhibitors Market Trends
- 2.2.2. Market Recommendations
- 2.3. Porter's Five Forces Analysis for the Interleukin inhibitors Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes
- 3. Market Determinants
- 3.1. Market Drivers
- 3.1.1. Drivers For Global Interleukin inhibitors Market: Impact Analysis
- 3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Interleukin inhibitors Market: Impact Analysis
- 3.3. Market Opportunities
- 3.3.1. Opportunities For Global Interleukin inhibitors Market: Impact Analysis
- 4. Competitive Landscape
- 4.1. Competitive Dashboard – Interleukin inhibitors Market Revenue and Share by Manufacturers
- Interleukin inhibitors Product Comparison Analysis
- Top Market Player Ranking Matrix
- 4.2. Key Company Analysis
- 4.2.1. AbbVie Inc.
- 4.2.1.1. Overview
- 4.2.1.2. Product Portfolio
- 4.2.1.3. Financial Analysis
- 4.2.1.4. SWOT Analysis
- 4.2.1.5. Business Strategy
- 4.2.2. Eli Lilly and Company
- 4.2.2.1. Overview
- 4.2.2.2. Product Portfolio
- 4.2.2.3. Financial Analysis
- 4.2.2.4. SWOT Analysis
- 4.2.2.5. Business Strategy
- 4.2.3. Johnson & Johnson Services, Inc.
- 4.2.3.1. Overview
- 4.2.3.2. Product Portfolio
- 4.2.3.3. Financial Analysis
- 4.2.3.4. SWOT Analysis
- 4.2.3.5. Business Strategy
- 4.2.4. Novartis AG
- 4.2.4.1. Overview
- 4.2.4.2. Product Portfolio
- 4.2.4.3. Financial Analysis
- 4.2.4.4. SWOT Analysis
- 4.2.4.5. Business Strategy
- 4.2.5. Sanofi S.A.
- 4.2.5.1. Overview
- 4.2.5.2. Product Portfolio
- 4.2.5.3. Financial Analysis
- 4.2.5.4. SWOT Analysis
- 4.2.5.5. Business Strategy
- 4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration
- 5. Global Interleukin inhibitors Market Sales Analysis by Type ($ Million)
- 5.1. IL-17
- 5.2. IL-23
- 5.3. IL-1
- 5.4. IL-5
- 5.5. IL-6
- 5.6. Others
- 6. Global Interleukin inhibitors Market Sales Analysis by Application ($ Million)
- 6.1. Hospital-Based Laboratories
- 6.2. Stand-Alone Laboratories
- 6.3. Clinic-Based Labor
- 6.4. Others
- 7. Regional Analysis
- 7.1. North American Interleukin inhibitors Market Sales Analysis – Type Application Country ($ Million)
- Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
- 7.2. European Interleukin inhibitors Market Sales Analysis – Type Application Country ($ Million)
- Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
- 7.3. Asia-Pacific Interleukin inhibitors Market Sales Analysis – Type Application Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
- 7.4. Rest of the World Interleukin inhibitors Market Sales Analysis – Type Application Country ($ Million)
- Macroeconomic Factors for Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa
- 8. Company Profiles
- 8.1. AbbVie Inc.
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
- 8.2. Amgen Inc.
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
- 8.3. Astellas Pharma Inc.
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
- 8.4. AstraZeneca plc
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
- 8.5. Bausch Health Companies Inc.
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
- 8.6. Biogen Inc.
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
- 8.7. Bristol-Myers Squibb Company
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
- 8.8. Eli Lilly and Company
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
- 8.9. F. Hoffmann-La Roche Ltd
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
- 8.10. GlaxoSmithKline plc
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
- 8.11. Johnson & Johnson Services, Inc.
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
- 8.12. Kyowa Kirin Co., Ltd.
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
- 8.13. Merck & Co., Inc.
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
- 8.14. Novartis AG
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
- 8.15. Pfizer Inc.
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
- 8.16. Regeneron Pharmaceuticals, Inc.
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
- 8.17. Sanofi S.A.
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
- 8.18. Sun Pharmaceutical Industries Ltd.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
- 8.19. Takeda Pharmaceutical Company Ltd.
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
- 8.20. Teva Pharmaceutical Industries Ltd.
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
